Articles From: Bimini Capital Management Announces Second Quarter 2013 Results to Bio-Rad Announces the Appointment of New Board Member


2013/8/5
VERO BEACH, Fla., Aug.
Sign-up for Bimini Capital Management Announces Second Quarter 2013 Results investment picks
2013/12/12
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins ™ , announced today that it has amended its development and commercialization collaboration agreement with Amgen Inc. to extend the period during which Amgen may exercise its option by six months.
Sign-up for BIND Therapeutics and Amgen Amend Collaboration Agreement for Kinase Inhibitor Nanomedicine investment picks
2013/9/25
BIND Therapeutics, Inc. (NASDAQ: BIND) announced today the closing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, resulting in gross proceeds of $70,500,000 before underwriting discounts and commissions.
Sign-up for BIND Therapeutics Announces Closing of Initial Public Offering investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced that Greg Berk, M.D., Chief Medical Officer, will be leaving BIND to pursue another opportunity.
Sign-up for BIND Therapeutics Announces Departure of Chief Medical Officer investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that the company’s co-founders have published data demonstrating the successful engineering of targeted nanoparticles to cross biological barriers, such as the intestinal barrier, and enter the bloodstream, potentially broadening future therapeutic applications for BIND’s Medicinal Nanoengineering platform.
Sign-up for BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles investment picks
2014/4/7
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting.
Sign-up for BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting investment picks
2014/3/3
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced that it has structured its management team for future growth by promoting and expanding the areas of responsibility for members of its management team.
Sign-up for BIND Therapeutics Promotes Key Executives: Organization Positioned for Continued Growth investment picks
2014/3/25
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today reported financial results for the fourth quarter and year-ended December 31, 2013.
Sign-up for BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today reported financial results for the three-month period ended September 30, 2013.
Sign-up for BIND Therapeutics Reports Third Quarter 2013 Financial Results investment picks
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that it will be added as a member of the Russell 2000 ® , Russell 3000 ® , Russell Global and Russell Microcap Indexes at the close of market today, December 20, 2013, as Russell Investments reconstitutes its comprehensive family of global indexes.
Sign-up for BIND Therapeutics to be Added to Russell Indexes on December 20, 2013 investment picks
2014/2/26
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the 26 th Annual Roth Conference in Laguna Nigel, CA on Monday, March 10, 2014 at 11:30 a.m. PT.
Sign-up for BIND Therapeutics to Present at 26th Annual Roth Conference investment picks
2014/2/24
BIND Therapeutics, Inc. (NASDAQ:BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the Cowen 34 th Annual Healthcare Conference in Boston on Tuesday, March 4, 2014 at 10:40 a.m. ET.
Sign-up for BIND Therapeutics to Present at Cowen 34th Annual Healthcare Conference investment picks
2014/1/28
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that Scott Minick, BIND’s President and CEO, is scheduled to present at the following healthcare conferences during February 2014: Interested parties may access a live webcast of the presentations by visiting the BIND Therapeutics website at www.bindtherapeutics.com .
Sign-up for BIND Therapeutics to Present at February Healthcare Conferences investment picks
2014/3/5
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that three poster presentations including clinical data on its lead drug candidate, BIND-014 and preclinical data on its AstraZeneca collaboration based on Barasertib (AZD1152), will be presented at the upcoming American Association of Cancer Research (AACR) meeting which takes place April 5-9, 2014 in San Diego, CA.
Sign-up for BIND Therapeutics to Present Data at the AACR 2014 Annual Meeting investment picks
2014/3/18
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced it will report fourth quarter and year ended December 31, 2013 financial results on Tuesday, March 25, 2014.
Sign-up for BIND Therapeutics to Report Fourth Quarter and Year End 2013 Financial Results and Business Developments on March 25, 2014 investment picks
2013/10/29
BIND Therapeutics, Inc. (NASDAQ: BIND) a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , announced today that it will report financial results for the third quarter ended September 30, 2013 on Tuesday, November 5, 2013.
Sign-up for BIND Therapeutics to Report Third Quarter 2013 Financial Results and Business Developments on November 5, 2013 investment picks
2014/3/19
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins TM , today announced that Company management will ring the Opening Bell at the NASDAQ MarketSite in Times Square, New York at 9:30 a.m. ET on Wednesday, March 26, 2014.
Sign-up for BIND Therapeutics to Ring the NASDAQ Stock Market Opening Bell on March 26, 2014 investment picks
2014/3/25
ADVISORY, March 25, 2014 (GLOBE NEWSWIRE) -- What: BIND Therapeutics, Inc. [BIND], a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, will visit the NASDAQ MarketSite in New York City's Times Square.
Sign-up for BIND Therapeutics, Inc. [BIND] to Ring The NASDAQ Stock Market Opening Bell investment picks
2013/8/21
Bing launches national pilot program that gives schools the choice to avoid the commercialization of their students' Web searches.
Sign-up for Bing launches Bing for Schools: An ad-free search zone for schools investment picks
2013/12/2
The most-searched people, music, movies, technology, fashion, sports and travel destinations from 12 countries around the world unveiled at http://www.BingTrends.com. REDMOND, Wash.
Sign-up for Bing shares the top global searches of 2013 investment picks
2014/1/27
Opportunity for Americans to share their views by "voting" on President Obama's address and the Republican response; Bing Pulse received 12.9 million votes during the 2013 State of the Union, making it the largest live online poll in history; new features include an annotated graph allowing users to see what passages are soaring and tanking, and poll questions about key topics in the speeches.
Sign-up for Bing.com and FOX News Channel team up to bring real-time polling to the State of the Union investment picks
With Bing Pulse, viewers become a part of the conversation.
Sign-up for Bing.com and FOX News team up to bring real-time online polling to nightly news; Bing Pulse featured on "Special Report with Bret Baier" investment picks
2014/1/3
This Sunday, TVGN (TV Guide Network) will offer viewers an exclusive TV catch-up of all 13 episodes of HOSTAGES, a high-octane suspense drama airing on the CBS Television Network.
Sign-up for Binge TV Continues on TVGN (TV Guide Network) with All-Day Marathon of CBS’ “HOSTAGES” on Sunday, January 5 investment picks
2014/2/26
By Quentin Fottrell If you haven't started watching Netflix's "House of Cards," now might be a good time--the video streaming site's deal with Comcast should make binging on TV shows easier on the eyes.
Sign-up for Binge viewing: Now with fewer hiccups investment picks
ENGLEWOOD, Colo., Sept.
Sign-up for Bio-Industry Veteran Greg Roda Joins Gevo investment picks
2014/2/18
WALL, N.J. and WILMINGTON, Del., Feb.
Sign-up for BIO-key and InterDigital to Introduce OpenID Based Secure Multifactor Authentication for Android Smartphones at Mobile World Congress investment picks
2014/4/1
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the year 2013.
Sign-up for Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results investment picks
2014/3/26
Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that Dr.
Sign-up for Bio-Path Holdings, Inc. Appoints Ulrich W. Mueller Chief Operating Officer investment picks
2014/4/10
http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1106120&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad Acquires GnuBIO and DNA Sequencing Technology investment picks
2013/12/10
http://media.marketwire.com/attachments/201308/181926_BIO-RADLOGO.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1075263&ProfileId=051205&sourceType=1 HERCULES, CA --
Sign-up for Bio-Rad Announces the Appointment of New Board Member investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Bimini Capital Management Announces Second Quarter 2013 Results to Bio-Rad Announces the Appointment of New Board Member
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity